BofA lowered the firm’s price target on Integra LifeSciences to $18 from $26 and keeps an Underperform rating on the shares. Several of Integra’s operational challenges over the last two years have proven hard to overcome and the company needs to stabilize the business to restore investor confidence, says BofA, which adds that the company continues to set “what we see as overly optimistic expectations that leave little room for error.” The firm fears that Integra has again set expectations for Q4 and 2025 “too high,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences upgraded to Neutral from Sell at BTIG
- Integra LifeSciences price target lowered to $16 from $20 at Citi
- Integra LifeSciences price target lowered to $20 from $22 at BTIG
- Integra LifeSciences price target lowered to $20 from $23 at Citi